Treatment with GH, on the other hand, aims to normalize IGF-1 levels as much as possible and is not expected to induce a sustained excess of IGF-1, as in acromegaly or in patients with diabetic retinopathy. The gene discussed is GH1; the disease is diabetic retinopathy.